Widespread use of neuraminidase inhibitors in Japan

Journal of Infection and Chemotherapy

Volumn 17, Issue 5, 2011, Pages 595-601

  Sugaya, Norio ^a  

^a Keiyu Hospital   (Japan)

Author keywords

Influenza; Laninamivir; Neuraminidase inhibitor; Oseltamivir; Pandemic; Peramivir; Zanamivir

Indexed keywords

FAVIPIRAVIR; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ABNORMAL BEHAVIOR; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BINDING AFFINITY; CROSS RESISTANCE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG USE; EARLY INTERVENTION; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA B; JAPAN; MORTALITY; NONHUMAN; PRESCRIPTION; PREVALENCE; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84855436488     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0288-0     Document Type: Review

References (34)

1. Sugaya N, Mitamura K, Hatakeyama S, Kiso M, Kawaoka Y. Lower clinical effectiveness of oseltamivir against influenza B infection. The 2nd European Influenza Conference, Malta, 11-14 September 2005.
2. Sugaya N, Tamura D, Yamazaki M, Ichikawa M, Kawakami C, Kawaoka Y, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis. 2008;47(3):339-45. (Pubitemid 352009352)
3. Sakai-Tagawa Y, Ozawa M, Tamura D, Le MQ, Nidom CA, Sugaya N, et al. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol. 2010;48(8):2872-7.
4. Ministry of Health, Welfare and Labour, Japan. Infectious Diseases Weekly Report Japan (IDWR). 2010;12:10-5. Available at http://idsc.nih.go.jp/idwr/ kanja/idwr/idwr2010/idwr2010-10.pdf.
5. Louie JK, Acosta M, Jamieson DJ, Honein MA. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2009;362(1):27-35.
6. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children. J Infect 2011.
7. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
8. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20): 1935-44.
9. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA. 2009;302(17): 1880-7.
10. Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L, Kettner J, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. Can Med Assoc J. 2010;182(3):257-64.
11. Sachedina N, Donaldson LJ. Paediatric mortality related to pandemic influenza A H1N1 infection in England: An observational population-based study. Lancet. 2010;376(9755):1846-52.
12. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54(6):2575-82.
13. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167-75.
14. Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55(6):2803-12.
15. Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102.
16. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA. 2010;107(2):882-7.
17. Bantia S, Parker CD, Ananth SL, Horn LL, Andries K, Chand P, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother. 2001;45(4):1162-7. (Pubitemid 32230997)
18. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73(3):228-31.
19. Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008;80(2):150-7.
20. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568-74.
21. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69(1):39-45. (Pubitemid 41790480)
22. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother. 2005;49(11):4515-20. (Pubitemid 41552580)
23. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother. 2009;53(1):186-92.
24. Kiso M, Kubo S, Ozawa M, Le QM, Nidom CA, Yamashita M, et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog. 2010;6(2):e1000786.
25. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol. 2010;50(11): 1319-29.
26. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44(2):197-202. (Pubitemid 46079980)
27. Huang YC, Lin TY, Wu SL, Tsao KC. Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. Pediatr Infect Dis J. 2003;22(4):366-8.
28. Okumura A, Nakano T, Fukumoto Y, Higuchi K, Kamiya H, Watanabe K, et al. Delirious behavior in children with influenza: Its clinical features and EEG findings. Brain Dev. 2005;27(4):271-4. (Pubitemid 40602868)
29. Ministry of Health, Labor and Welfare. Vital Statistics of Japan. Available at: Http://www.e-stat.go.jp/SG1/estat/GL08020101. do?-toGL08020101- &tstatCode=000001028897&requestSender= dsearch.
30. Fuke C, Ihama Y, Miyazaki T. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. Leg Med (Tokyo). 2008;10(2):83-7.
31. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Vahlberg T, Ziegler T, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: A randomized controlled trial. Clin Infect Dis. 2010;51(8):887-94.
32. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20(2):127-33. (Pubitemid 32151932)
33. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2009;339:b3172.
34. Ministry of Health, Welfare and Labour, Japan. Infectious Agents Surveillance Report (IASR). 2011. Available at: Http://idsc.nih. go.jp/iasr/rapid/pr3641.html.